
Arthroplasty
AAOS 2015: No difference between topical and intravenous tranexamic acid for TKA
131 patients undergoing total knee arthroplasty were randomized to receive tranexamic acid either topically, with 2mg injected intra-articularly following capsular closure, or 1 mg intravenously prior to tourniquet inflation and another 1mg prior to tourniquet deflation. Postoperative hemoglobin levels and cumulative blood loss were assessed for 3 days postoperatively, and length of stay, discharge location, and complication rates were recored. There were no observed significant differences between the two groups in any of the outcomes assessed.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.